LQDA

LifeSci Capital Initiates Coverage of Liquidia (LQDA) with Outperform Recommendation

Fintel reports that on October 3, 2024, LifeSci Capital initiated coverage of Liquidia (NasdaqCM:LQDA) with a Outperform recommendation.

Analyst Price Forecast Suggests 142.38% Upside

As of September 25, 2024, the average one-year price target for Liquidia is $24.48/share. The forecasts range from a low of $17.17 to a high of $30.45. The average price target represents an increase of 142.38% from its latest reported closing price of $10.10 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Liquidia is 77MM, an increase of 418.85%. The projected annual non-GAAP EPS is -0.54.

What is the Fund Sentiment?

There are 268 funds or institutions reporting positions in Liquidia. This is an increase of 4 owner(s) or 1.52% in the last quarter. Average portfolio weight of all funds dedicated to LQDA is 0.40%, an increase of 20.46%. Total shares owned by institutions increased in the last three months by 0.64% to 47,749K shares. LQDA / Liquidia Corporation Put/Call Ratios The put/call ratio of LQDA is 0.84, indicating a bullish outlook.

What are Other Shareholders Doing?

LQDA / Liquidia Corporation Shares Held by Institutions

Caligan Partners holds 10,361K shares representing 12.28% ownership of the company. No change in the last quarter.

Patient Square Capital holds 7,183K shares representing 8.51% ownership of the company. No change in the last quarter.

Findell Capital Management holds 2,400K shares representing 2.84% ownership of the company. In its prior filing, the firm reported owning 2,105K shares , representing an increase of 12.29%. The firm decreased its portfolio allocation in LQDA by 14.66% over the last quarter.

Farallon Capital Management holds 2,055K shares representing 2.44% ownership of the company. No change in the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,883K shares representing 2.23% ownership of the company. In its prior filing, the firm reported owning 1,533K shares , representing an increase of 18.58%. The firm decreased its portfolio allocation in LQDA by 2.83% over the last quarter.

Liquidia Background Information
(This description is provided by the company.)

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT technology. The Company operates through two subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies is developing two product candidates: LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH), and LIQ865, an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain for three to five days after a procedure. Liquidia PAH, LLC provides commercialization for rare disease pharmaceutical products, such as Treprostinil Injection, Sandoz Inc.'s first-to-file, generic treprostinil for PAH.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.